Cargando…

Therapeutic Advances in Immunotherapies for Hematological Malignancies

Following the success of immunotherapies such as chimeric antigen receptor transgenic T-cell (CAR-T) therapy, bispecific T-cell engager therapy, and immune checkpoint inhibitors in the treatment of hematologic malignancies, further studies are underway to improve the efficacy of these immunotherapie...

Descripción completa

Detalles Bibliográficos
Autores principales: Nogami, Ayako, Sasaki, Koji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9569660/
https://www.ncbi.nlm.nih.gov/pubmed/36232824
http://dx.doi.org/10.3390/ijms231911526
_version_ 1784809909398798336
author Nogami, Ayako
Sasaki, Koji
author_facet Nogami, Ayako
Sasaki, Koji
author_sort Nogami, Ayako
collection PubMed
description Following the success of immunotherapies such as chimeric antigen receptor transgenic T-cell (CAR-T) therapy, bispecific T-cell engager therapy, and immune checkpoint inhibitors in the treatment of hematologic malignancies, further studies are underway to improve the efficacy of these immunotherapies and to reduce the complications associated with their use in combination with other immune checkpoint inhibitors and conventional chemotherapy. Studies of novel therapeutic strategies such as bispecific (tandem or dual) CAR-T, bispecific killer cell engager, trispecific killer cell engager, and dual affinity retargeting therapies are also underway. Because of these studies and the discovery of novel immunotherapeutic target molecules, the use of immunotherapy for diseases initially thought to be less promising to treat with this treatment method, such as acute myeloid leukemia and T-cell hematologic tumors, has become a reality. Thus, in this coming era of new transplantation- and chemotherapy-free treatment strategies, it is imperative for both scientists and clinicians to understand the molecular immunity of hematologic malignancies. In this review, we focus on the remarkable development of immunotherapies that could change the prognosis of hematologic diseases. We also review the molecular mechanisms, development processes, clinical efficacies, and problems of new agents.
format Online
Article
Text
id pubmed-9569660
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95696602022-10-17 Therapeutic Advances in Immunotherapies for Hematological Malignancies Nogami, Ayako Sasaki, Koji Int J Mol Sci Review Following the success of immunotherapies such as chimeric antigen receptor transgenic T-cell (CAR-T) therapy, bispecific T-cell engager therapy, and immune checkpoint inhibitors in the treatment of hematologic malignancies, further studies are underway to improve the efficacy of these immunotherapies and to reduce the complications associated with their use in combination with other immune checkpoint inhibitors and conventional chemotherapy. Studies of novel therapeutic strategies such as bispecific (tandem or dual) CAR-T, bispecific killer cell engager, trispecific killer cell engager, and dual affinity retargeting therapies are also underway. Because of these studies and the discovery of novel immunotherapeutic target molecules, the use of immunotherapy for diseases initially thought to be less promising to treat with this treatment method, such as acute myeloid leukemia and T-cell hematologic tumors, has become a reality. Thus, in this coming era of new transplantation- and chemotherapy-free treatment strategies, it is imperative for both scientists and clinicians to understand the molecular immunity of hematologic malignancies. In this review, we focus on the remarkable development of immunotherapies that could change the prognosis of hematologic diseases. We also review the molecular mechanisms, development processes, clinical efficacies, and problems of new agents. MDPI 2022-09-29 /pmc/articles/PMC9569660/ /pubmed/36232824 http://dx.doi.org/10.3390/ijms231911526 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Nogami, Ayako
Sasaki, Koji
Therapeutic Advances in Immunotherapies for Hematological Malignancies
title Therapeutic Advances in Immunotherapies for Hematological Malignancies
title_full Therapeutic Advances in Immunotherapies for Hematological Malignancies
title_fullStr Therapeutic Advances in Immunotherapies for Hematological Malignancies
title_full_unstemmed Therapeutic Advances in Immunotherapies for Hematological Malignancies
title_short Therapeutic Advances in Immunotherapies for Hematological Malignancies
title_sort therapeutic advances in immunotherapies for hematological malignancies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9569660/
https://www.ncbi.nlm.nih.gov/pubmed/36232824
http://dx.doi.org/10.3390/ijms231911526
work_keys_str_mv AT nogamiayako therapeuticadvancesinimmunotherapiesforhematologicalmalignancies
AT sasakikoji therapeuticadvancesinimmunotherapiesforhematologicalmalignancies